The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants.
Antidepressants
Roux-en-Y Gastric Bypass
Therapeutic drug monitoring
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
08
08
2022
accepted:
23
02
2023
revised:
17
02
2023
medline:
5
5
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
Roux-en-Y gastric bypass (RYGB) involves alterations of the gastrointestinal tract resulting in altered absorption. Patients with obesity have a higher prevalence of depression, and antidepressants are often prescribed. Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse. The aim of this study was to describe the evolution of trough drug dose-normalized antidepressant plasma concentrations before and after RYGB. This naturalistic prospective case series considers patients with trough plasma concentrations in a 1-year timeframe before and after RYGB. Only antidepressants prescribed to at least three patients were included in the present study. Thirteen patients (n = 12 females, median age 44 years, median BMI before intervention = 41.3 kg/m This study shows a decrease in plasma antidepressant concentrations following RYGB. TDM before and after RYGB, in addition to close monitoring of psychiatric symptomatology, may help optimize antidepressant treatment after bariatric surgery. These results also highlight the need for prospective studies assessing the clinical evidence available through TDM in these patients.
Identifiants
pubmed: 36949223
doi: 10.1007/s11695-023-06526-1
pii: 10.1007/s11695-023-06526-1
pmc: PMC10156620
doi:
Substances chimiques
Fluoxetine
01K63SUP8D
Trazodone
YBK48BXK30
Escitalopram
4O4S742ANY
Duloxetine Hydrochloride
9044SC542W
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1422-1430Informations de copyright
© 2023. The Author(s).
Références
Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220–9.
doi: 10.1001/archgenpsychiatry.2010.2
pubmed: 20194822
Gill H, Kang S, Lee Y, et al. The long-term effect of bariatric surgery on depression and anxiety. J Affect Disord. 2019;246:886–94.
doi: 10.1016/j.jad.2018.12.113
pubmed: 30795495
Tindle HA, Omalu B, Courcoulas A, et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010;123(11):1036–42.
doi: 10.1016/j.amjmed.2010.06.016
pubmed: 20843498
pmcid: 4296730
Kennedy AL, Nelson T, Pettine S, et al. Medication use following bariatric surgery: factors associated with early discontinuation. Obes Surg. 2014;24(5):696–704.
doi: 10.1007/s11695-013-1131-8
pubmed: 24234778
pmcid: 4016176
Yuen KH. The transit of dosage forms through the small intestine. Int J Pharm. 2010;395(1–2):9–16.
doi: 10.1016/j.ijpharm.2010.04.045
pubmed: 20478371
Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34(6):1295–300.
doi: 10.2337/dc10-2140
pubmed: 21478461
pmcid: 3114332
Fuller AK, Tingle D, DeVane CL, et al. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol. 1986;6(6):376–8.
pubmed: 3805335
Tripp AC. Lithium toxicity after Roux-en-Y gastric bypass surgery. J Clin Psychopharmacol. 2011;31(2):261–2.
doi: 10.1097/JCP.0b013e318210b203
pubmed: 21364348
McGrane IR, Salyers LA, Molinaro JR, et al. Roux-en-Y gastric bypass and antipsychotic therapeutic drug monitoring: two cases. J Pharm Pract. 2021;34(3):503–6.
doi: 10.1177/0897190020905467
pubmed: 32067562
Steffen KJ, Mohammad AS, Roerig JL, et al. Lisdexamfetamine pharmacokinetic comparison between patients who underwent Roux-en-Y gastric bypass and nonsurgical controls. Obes Surg. 2021;31(10):4289–94.
doi: 10.1007/s11695-020-04969-4
pubmed: 34291361
Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8(1):62–6.
doi: 10.1016/j.soard.2010.12.003
pubmed: 21256091
Roerig JL, Steffen KJ, Zimmerman C, et al. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol. 2013;33(4):479–84.
doi: 10.1097/JCP.0b013e3182905ffb
pubmed: 23771193
Krieger CA, Cunningham JL, Reid JM, et al. Comparison of bioavailability of single-dose extended-release venlafaxine capsules in obese patients before and after gastric bypass surgery.Ther Drug Monit . 2002;24(4):563–6.
doi: 10.1002/phar.2022
pubmed: 28845898
Marzinke MA, Petrides AK, Steele K, et al. Decreased escitalopram concentrations post-Roux-en-Y gastric bypass surgery. Ther Drug Monit. 2015;37(3):408–12.
doi: 10.1097/FTD.0000000000000146
pubmed: 25970510
Vandenberghe F, Gilet P, Daali Y, et al. Bioavailability of vortioxetine after a Roux-en-Y gastric bypass. Obes Surg. 2021;31(3):1353–6.
doi: 10.1007/s11695-020-05048-4
pubmed: 33063155
Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169(3):256–63.
doi: 10.1176/appi.ajp.2011.11050719
pubmed: 22407114
pmcid: 3583374
Wallerstedt SM, Nylen K, Axelsson MAB. Serum concentrations of antidepressants, antipsychotics, and antiepileptics over the bariatric surgery procedure. Eur J Clin Pharmacol. 2021;77(12):1875–85.
doi: 10.1007/s00228-021-03182-1
pubmed: 34269840
pmcid: 8585833
Busetto L, Dicker D, Azran C, et al. Obesity management task force of the European Association for the Study of Obesity Released “Practical Recommendations for the Post-Bariatric Surgery Medical Management.” Obes Surg. 2018;28(7):2117–21.
doi: 10.1007/s11695-018-3283-z
pubmed: 29725979
Sogg S, Lauretti J, West-Smith L. Recommendations for the presurgical psychosocial evaluation of bariatric surgery patients. Surg Obes Relat Dis. 2016;12(4):731–49.
doi: 10.1016/j.soard.2016.02.008
pubmed: 27179400
Directives pour le traitement chirurgical de l’obésité: Swiss Society for the Study of Morbid Obesity and Metabolic Disorders; 2021 [updated 01.07.2021. Available from: https://www.smob.ch/fr/directives/medicales .
Ankier SI, Warrington SJ, Sneddon JM. A pharmacokinetic and dynamic study of single nightly doses of conventional and controlled release formulations of trazodone. Methods Find Exp Clin Pharmacol. 1991;13(2):121–7.
pubmed: 2072810
Mihara K, Yasui-Furukori N, Kondo T, et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-Chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit. 2002;24(4):563–6.
doi: 10.1097/00007691-200208000-00016
pubmed: 12142643
Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40(2):161–7.
doi: 10.1177/00912700022008810
pubmed: 10664922
Sogaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45(12):1400–6.
doi: 10.1177/0091270005280860
pubmed: 16291715
Prozac Drug Approval Package: U.S. Food and Drug Administration; 1987 [updated 2017.
Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62.
pubmed: 28910830
Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021.
Duvoisin C, Favre L, Allemann P, et al. Roux-en-Y gastric bypass: ten-year results in a cohort of 658 patients. Ann Surg. 2018;268(6):1019–25.
doi: 10.1097/SLA.0000000000002538
pubmed: 29194086
Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998;26(6):572–5.
pubmed: 9616194
Plaeke P, Van Den Eede F, Gys B, et al. Postoperative continuation of antidepressant therapy is associated with reduced short-term weight loss following Roux-en-Y gastric bypass surgery. Langenbecks Arch Surg. 2019;404(5):621–31.
doi: 10.1007/s00423-019-01784-z
pubmed: 30969361
Hawkins M, Leung SE, Lee A, et al. Psychiatric medication use and weight outcomes one year after bariatric surgery. Psychosomatics. 2020;61(1):56–63.
doi: 10.1016/j.psym.2019.10.009
pubmed: 31806241
Courcoulas AP, King WC, Belle SH, et al. Seven-year weight trajectories and health outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. JAMA Surg. 2018;153(5):427–34.
doi: 10.1001/jamasurg.2017.5025
pubmed: 29214306
Geerts MM, van den Berg EM, van Riel L, et al. Behavioral and psychological factors associated with suboptimal weight loss in post-bariatric surgery patients. Eat Weight Disord. 2021;26(3):963–72.
doi: 10.1007/s40519-020-00930-7
pubmed: 32472495
Switzer NJ, Debru E, Church N, et al. The impact of bariatric surgery on depression: a review. Curr Cardiovasc Risk Rep. 2016;10(3):12.
doi: 10.1007/s12170-016-0492-7
Azran C, Wolk O, Zur M, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev. 2016;17(11):1050–66.
doi: 10.1111/obr.12434
pubmed: 27335140